Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+…
By daniellenierenberg
BOSTON, July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Ziopharm or the Company) (Nasdaq:ZIOP), today announced the initiation of a phase 1 clinical trial to evaluate CD19-specific CAR-T, using its Rapid Personalized Manufacturing (RPM) technology, as an investigational treatment for patients with relapsed CD19+ leukemias and lymphomas. The trial is now open for enrollment at The University of Texas MD Anderson Cancer Center.
In this trial, the Company utilizes its non-viral Sleeping Beauty genetic engineering technology to infuse CAR-T the day after electroporation. Ziopharms RPM CD19-specific CAR-T therapy results from the stable, non-viral insertion of DNA into the genome of resting T cells to co-express the chimeric antigen receptor (CAR), membrane-bound IL-15 (mbIL15) and a safety switch.
We are pleased to expand the scope of our clinical development with MD Anderson, as we seek to evaluate our RPM technology using CD19-specific CAR-T cells, said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. RPM is a promising manufacturing solution, as T cells from the bloodstream are genetically reprogramed with DNA plasmids from the Sleeping Beauty system and then simply administered the next day.
Our CAR-T therapy can be administered at low cell doses, which may control cytokine release syndrome and is appealing for the treatment of patients including those with CD19-expressing malignancies that have relapsed after allogeneic bone marrow transplantation (BMT). There are limited effective treatment options for such patients as evidenced by the low rate of remission and poor long-term survival, Dr. Cooper added.
Up to 24 patients with advanced CD19+ leukemias and lymphomas who have relapsed after allogeneic BMT will be enrolled in this investigator-initiated trial (NCT03579888). The primary endpoint of the study is to determine the safety and maximum tolerated dose of donor-derived genetically modified CD19-specific T cells manufactured using the RPM process. An additional study is planned through Ziopharms joint venture with Eden BioCell to evaluate the RPM technology using patient-derived (autologous) CD19-specific CAR-T in Greater China.
Research reveals three-year survival for adults with CD19+ acute lymphoblastic leukemia after allogeneic BMT ranges from 30% to 65%.1 For patients with other CD19+ cancers, allogeneic BMT can provide three-year survival rates between 30% to 75%.1 Few patients experience a durable remission following allogeneic BMT, regardless of the treatment modality, with some having a median survival of only 2 to 3 months.2
About Ziopharm Oncology, Inc.Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the bodys immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharms pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic collaborations with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Regeneron Pharmaceuticals. For more information, please visit http://www.ziopharm.com.
Forward-Looking Statements DisclaimerThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the progress, design and timing of the Company's research and development programs, the potential benefits of the Companys therapies, and the Companys expectations regarding the number of patients in its clinical trials. Although Ziopharms management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharms product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the U.S. Food and Drug Administration or equivalent foreign regulatory agencies to conduct clinical trials and whether and when, if at all, they will receive final approval from the U.S. FDA or equivalent foreign regulatory agencies and for which indication; the strength and enforceability of Ziopharms intellectual property rights; competition from other pharmaceutical and biotechnology companies as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Ziopharm, including those risks and uncertainties listed in Ziopharms Quarterly Report on Form 10-Q filed by Ziopharm with the Securities and Exchange Commission. We are providing this information as of the date of this press release, and Ziopharm does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.
Investor Relations Contacts:Ziopharm Oncology:Chris TaylorVP, Investor Relations and Corporate CommunicationsT: 617.502.1881E: ctaylor@ziopharm.com
LifeSci Advisors:Mike MoyerManaging DirectorT: 617.308.4306E: mmoyer@lifesciadvisors.com
Media Relations Contact:LifeSci Communications:Patrick BurseyT: 646.876.4932E: pbursey@lifescicomms.com
1 D'Souza A, Fretham C. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT): CIBMTR Summary Slides, 2018. Available at https://www.cibmtr.org
2 Keil F, Prinz E, Kalhs P, et al. Treatment of leukemic relapse after allogeneic stem cell transplantation with cytotoreductive chemotherapy and/or immunotherapy or second transplants. Leukemia 2001; 15:355-361.
Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen…
By daniellenierenberg
Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Hematopoietic Stem Cells Transplantation Market which would mention How the Covid-19 is affecting the Hematopoietic Stem Cells Transplantation Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Hematopoietic Stem Cells Transplantation Players to Combat Covid-19 Impact.
Hematopoietic stem cell transplantation (HSCT) includes the intravenous infusion of autologous or allogeneic stem cells composed from bone marrow, or umbilical cord blood, peripheral blood to reestablish hematopoietic purpose in patients whose bone marrow or immune system is dented or flawed.
Request for sample report:
https://www.reportconsultant.com/request_sample.php?id=70734
Report Consultant has recently added a new Report on Hematopoietic Stem Cells Transplantation Market into its largest Database. It gives the complete report on trends, growth, and opportunity, restraint. Along with this, it delivers a comprehensive description of the key players of different regions.
Leading Players Hematopoietic Stem Cells Transplantation Market:
Escape Therapeutics, Lonza Group, Regen BioPharma Inc, Cesca Therapeutics Inc., Cryo-Save AG, CBR Systems, Inc., Pluristem Therapeutics Inc., China Cord Blood Corporation, and ViaCord Inc.
It contains an enormous database containing numerous market segments and sub-segments. The study also provides importance on the latest daises along with the effect of certain platforms on market growth.
Ask for Discount on This Report:
https://www.reportconsultant.com/ask_for_discount.php?id=70734
Market Segmentation: The market is segmented on the basis of type, application, and region.
Market Segmentation by Type:
Market Segmentation by Application:
Market Segmentation by Regions:
To achieve this, the Report Consultant has given prime importance to the exploration techniques for global clients and potential clients. Reaching out towards global clients has become a vital part to succeed in the Hematopoietic Stem Cells Transplantation Market. It offers SWOT analysis to identify the various significant business parameters such as strengths, weaknesses, threats, and opportunities which support to decision-makers to formulate the data-driven decisions in businesses.
Buy an exclusive Report:
https://www.reportconsultant.com/checkout?id=70734
Reasons for buying this research report:
About us:
Report Consultant A global leader in analytics, research, and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations, and information using our experienced skills and verified methodologies.
Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.
Contact us:
Rebecca Parker
(Report Consultant)
Contact No: +81-368444299
[emailprotected]
http://www.reportconsultant.com
Read the original:
Thriving Growth of Hematopoietic Stem Cells Transplantation Market Forecast 2020 with leading players Escape Therapeutics, Lonza Group, Regen...
Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -…
By daniellenierenberg
LONDON, July 6, 2020 /PRNewswire/ -- IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1
The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.
Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."
It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.
Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."
"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem," concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.
More About the Study1
In addition to this research, IVI are presenting three more studies at the ESHRE Congress:
These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7
More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients
To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.
IVIRMA Global and IVI London, UK
IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.comhttps://ivi-fertility.co.uk/
References
Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg
Seven ‘Sure’ Ways to Get Cancer – Curetoday.com
By daniellenierenberg
One cancer survivor looks at all the ways they might have gotten cancer, and wonders if any of those risk factors will factor into recurrence.
William Ramshaw resides in the expansive Pacific Northwest. He is a six-year survivor of pancreatic cancer and has written a memoir Gut Punched! Facing Pancreatic Cancer.
So, what would someone do to get cancer?
Use tobacco. Both my parents smoked packs a day. My brother chews. One of my best friends chain-smoked. I used to tell him, Dennis, this is going to kill you. He laughed. It did. Lost to esophageal cancer. Given those ominous Surgeon Generals Warnings, all caps and bolded, along with horrendous TV infomercials, I am mystified why people still use tobacco, but they do. Nicotine addiction is an awful thing.
Being overweight. Ok, this one is closer to home. Before getting pancreatic cancer, I had been a big guy. Not blimp-sized mind you but carrying pounds I didnt need. Post-surgery, I lost a third of my body weight, about 100 pounds. I have no butt. Yes, I can now wear those skinny jeans. Also, due to being replumbed, I cant even gain weight. Still, I wouldnt recommend my weight loss program to anyone. Its barbaric.
Getting too much sun. Growing up I plowed our orchard in my cutoffs with no shirt. By the end of summer, I was toasted brown. Looking back, I hope the layer of dirt shielded me from getting too many rays. Excess UV light is known to cause skin cancer. So far so good. I dont have any skin lesions yet.
Exposure to bad stuff. It seems everything I buy anymore comes with a warning such-and-such may cause cancer. I do pay attention but find myself unable to avoid exposure to everything that might be bad for me. At this point, I think breathing causes cancer. Should I stop breathing?
Breathing asbestos. Im a goner here too. As a former Navy-guy, I worked down in the boiler room. Hot as hell right there among gigantic steam pipes all encased in asbestos. Thankfully, so far, I have nothing other than a persistent cough and no lung cancer.
Worse draw an inside straight. (Also known as a gutshot or belly buster draw, where you have a straight but are missing the card in the middle.) While I dont play poker, getting cancer is a lot like drawing an inside straight. Our genes get messed up. Maybe we got them from a long-dead ancestor. One clicks over and we find ourselves with a losing cancer hand. Im not sure what happened in my case. My tumor was not genetically profiled. I wish it had been so I would better understand my odds at this point. Will I get another shot at a losing hand?
I know this in jest as no one tries or wants to get cancer. But its interesting to think about everything that causes cancer. Sadly, there are dozens of things. Cancer aside, I am indeed fortunate (and thankful) to be here.
Vor bags $110M to move engineered cell therapy into the clinic – FierceBiotech
By daniellenierenberg
CAR-T treatments and other immunotherapies have changed the treatment of some blood cancers, but they can target healthy cells as well as cancer cells, causing nasty side effects. Vor Biopharma is working on an engineered stem cell solution, and its raised $110 million to move its lead program into the clinic.
The Cambridge, Massachusetts-based company is developing the treatment, VOR33, for patients with acute myeloid leukemia (AML) whose disease has worsened despite undergoing chemotherapy or a stem cell transplant.
Thats the setting in which a lot of targeted agents are used. The trouble is, a great number of the targeted agents tend to failnot because they are not efficacious, but because the drug is too toxic for the patients bone marrow, Vor CEO Robert Ang told Fierce Biotech.
Fierce Innovation Awards: Life Sciences Edition 2020
Submit your entry to demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies.
The drugs home in on healthy cells as well as cancerous ones because they express the same proteins. This leads to myelosuppression, which means the bone marrow doesnt make enough white blood cells, platelets or red blood cells for the patient to survive, Ang said.
RELATED: Neon CBO Robert Ang jumps ship to take the helm at Vor Biopharma
Vors treatment is made from hematopoietic, or blood-forming, stem cells from healthy donors. The company uses gene editing to get rid of cancer drug targets in those cells that are biologically redundant, which means deleting them doesnt cause any harm. That target is CD33, in the case of VOR33.
Were trying to make the marrow treatment resistant such that the only cells that are expressing CD33 should be cancer cells, Ang said. We should be able to target them much more specifically, while minimizing the collateral damage that typically happens with these drugs.
RELATED: 5AM, JJDC get in on $42M series A round for cell therapy player Vor Biopharma
Vor believes its treatments could boost the reach of targeted therapies by improving their efficacy and increasing the amount of time patients can undergo those treatments.
And thats not all. In addition to protecting these transplants and the blood cells they produce from targeted drugs, Vor thinks its approach could change the way we think about bone marrow transplant.
To some degree, transplants have been relatively decentralized and less controlled A lot of hospitals develop their own unique practices as to what they think works and how to handle cells and process them, Ang said. Our product will be regulated by the FDA, so we will be able to provide controls and the proper manufacturing steps to ensure were making the best quality product for patients.
The series B will push VOR33 into clinical trials in the first half of 2021, a target the companys on track to meet despite the COVID-19 pandemic. And Vor plans to expand its portfolio beyond CD33, starting with an umbrella of targets in the myeloid space, namely in acute myeloid leukemia, myelodysplastic syndromes and related diseases.
But we are also looking beyond that to other cancers where there are similar potentially biologically redundant targets we could pursue, said Ang, who took the companys helm in August 2019.
Since then, Vor has grown from a staff of six to 50, and its about to move into new digs in west Cambridge as it moves VOR33 toward the clinic. Its got the backing of RA Capital Management, Fidelity, 5AM Ventures, Johnson & Johnson Innovation, Osage University Partners, PureTech Health, the Pagliuca Family Office and Alexandria Venture Investments to do it all.
Read more here:
Vor bags $110M to move engineered cell therapy into the clinic - FierceBiotech
200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy – ALS News Today
By daniellenierenberg
Patient dosing has finished in the pivotal Phase 3 trial assessing the safety and efficacy of repeat administrations of NurOwn, acell-based therapy forpeople with amyotrophic lateral sclerosis (ALS), BrainStorm Cell Therapeutics, the therapys developer, announced.
The Phase 3 trial (NCT03280056), which enrolled about 200 participants, is underway at six U.S. sites: the University of California, Irvine;Cedars-Sinai Medical Center;California Pacific Medical Center;Massachusetts General Hospital; the University of Massachusetts Medical School; and the Mayo Clinic.
Patients were randomly assigned to either three doses of NurOwn or a placebo, both administered every other month by injections directly into the spinal canal (intrathecal) over a period of four months.
The studys main goal is to assess the safety and efficacy of NurOwn, as measured by changes in the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R) score seen at 28 weeks (seven months) following the first treatment. ALSFRS-R assess such daily life abilities as swallowing, speaking, dressing and washing oneself, climbing stairs, and turning over in bed.
Secondary goals include treatment effects on the levels of several disease biomarkers, as found in samples of patients blood and cerebrospinal fluid (the liquid circulating in the brain and spinal cord).
BrainStorm expects top-line trial data to be available before the end of the year.
Completion of participant dosing in this clinical trial is an important milestone and brings us a step closer to potentially filing a biologics license application to make MSC-NTF cells [NurOwn] available to people with ALS, Chaim Lebovits, CEO of BrainStorm, said in the companyspress release.
NurOwn is a cell-based therapy that usesmesenchymal stem cells (MSCs) cells that are able to give rise to nearly all tissues found in the body, including bones, muscles, and connective tissue isolated from a patients own bone marrow.
After isolation, MSCs are grown in a lab dish and differentiated into cells that produce high levels of neurotrophic factors compounds that promote the growth and survival of nerve cells. The modified cells are then returned to patients through an injection into spinal canal.
Brainstorm is also investigating the potential of NurOwn treat other neurological disorders, including multiple sclerosis (MS), Huntingtons disease, Parkinsons disease, and autism spectrum disorder.
The open-label Phase 2 trial (NCT03799718) assessing three doses of NurOwn in people with progressive MSmay still be recruitingat two sites in the U.S. The cell-based therapy has not yet entered clinical testing for other disorders.
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.
Total Posts: 0
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
Read more from the original source:
200 ALS Patients Finish Dosing in Phase 3 Trial of NurOwn Cell Therapy - ALS News Today
Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 – 3rd Watch News
By daniellenierenberg
Hematopoietic Stem Cells Transplantation (HSCT) Marketreport provides in-depth COVID19 impact analysis ofMarket Overview, Product Scope, Market Drivers, Trends, Opportunities,Market Driving Force and Market Risks. It also profile the topmost prime manufacturers (Kite Pharma, Thermo Fisher Scientific, CellGenix Technologie Transfer, Cesca Therapeutics, R&D Systems) are analyzed emphatically by competitive landscape contrast, with respect toPrice, Sales,Capacity, Import, Export, Consumption, Gross, Gross Margin, Revenue and Market Share. Hematopoietic Stem Cells Transplantation (HSCT) industry breakdown data are shown at the regional level, to show the sales, revenue and growth by regions.Hematopoietic Stem Cells Transplantation (HSCT) Market describe Hematopoietic Stem Cells Transplantation (HSCT) Sales Channel,Distributors, Customers, Research Findings and Conclusion, Appendix and Data Source.
Key Target Audience of Hematopoietic Stem Cells Transplantation (HSCT) Market:Manufacturers of Hematopoietic Stem Cells Transplantation (HSCT), Raw material suppliers, Market research and consulting firms, Government bodies such as regulating authorities and policy makers, Organizations, forums and alliances related to Hematopoietic Stem Cells Transplantation (HSCT) market.
Get Free Sample PDF (including full TOC, Tables and Figures)of Hematopoietic Stem Cells Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2039940
In-Depth Qualitative Analyses Include Identification and Investigation Of The Following Aspects:Hematopoietic Stem Cells Transplantation (HSCT) Market Structure, Growth Drivers, Restraints and Challenges, Emerging Product Trends & Market Opportunities, Porters Fiver Forces.
Summary of Hematopoietic Stem Cells Transplantation (HSCT) Market:Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.
Over 30 years of studies in the field of blood-forming stem cells i.e. hematopoietic stem cells (HSC), researchers have developed significant understanding to use HSCs as a therapy. At present, no type of stem cell, adult, embryonic or fetal has attained such sufficient status. Hematopoietic stem cell transplantation (HSCT) is now routinely used for treating patients with malignant and non-malignant disorders of blood and the immune system. Currently, researchers have observed that through animal studies HSCs have the ability to form other cells such as blood vessels, muscles, and bone. Further application of this approach it may eventually be able to treat a wide array of conditions and replace ailing tissues. However, despite the vast experience with HSCs, researchers face major barriers in expanding their use beyond the replacement of immune and blood cells.
Hematopoietic stem cells are unable to proliferate and differentiate in-vitro. Researchers have yet to evolve an accurate method to differentiate stem cells from other cells derived from blood or bone marrow. Once such technical barriers are overcome, the avenues for realizing the full potential of HSCT. The type of transplant a person receives depends on several different factors, including the type and course of the disease, availability of suitable donors, and the patients overall health. There are three different sources of hematopoietic stem cells such as bone marrow, peripheral blood stem cells, and umbilical cord blood. The stem cell source used for a given transplant depends upon the underlying disease, the type of transplant (allogeneic or autologous), and size of the patient.
On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Hematopoietic Stem Cells Transplantation (HSCT) market foreach application, including-
Leukemia Lymphoproliferative Disorders Solid Tumors Non-Malignant Disorders Others
On the basis of product,this report displays the sales volume, revenue (Million USD), product price, market share and growth rate ofeach type, primarily split into-
Autologous Transplant Allogenic Transplant
Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2039940
Important Hematopoietic Stem Cells Transplantation (HSCT) Market Data Available In This Report:
Contact:
ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]
Browse More Reports Visit @https://bit.ly/2Sepby2
Read more here:
Hematopoietic Stem Cells Transplantation (HSCT) Market: Future Innovation Ways That, Growth & Profit Analysis, Forecast By 2026 - 3rd Watch News
One common infection could kill our baby girl but one simple act could change her life forever – The Sun
By daniellenierenberg
ONE simple act could save this little girl's life.
Little Shahera Khan has a fault with her immune system that means her body can't produce enough white blood cells.
3
It means the toddler is susceptible to infections, meaning a seemingly innocuous bug could kill her.
Shahera's life is very different to those of other tot's her age.
She can't go to nursery, make friends or really interact with too many other kids, for fear of picking up infections.
While she loves to play with her big brother, Amaan, five, she has to take daily medication and has blood transfusions each week.
If she picks up a common cold or cough, it can leave her in hospital for days while her tiny body fights the bacteria or virus.
Now, her parents are pleading for help from strangers, to offer their little girl a chance at a normal life.
Shahera's only hope of growing up like her peers is a stem cell transplant.
Speaking to The Sun her Mum Amina said she just wants her daughter to get better and to lead a normal life.
Shahera was born a healthy child and she was okay when she was small.
She picked up bronchiolitis when she was eight months old and had to be hospitalised. We were there for a week and she also picked up an ear and nose infection.
A lot of people say she has been through the wars and she has, she hasnt had an easy childhood and theres always something new with her illness
Amina, who lives in Croydon with Shahera, her husband and Sharehas little brother said that she had Shahera at home for just a couple of days before she had to go back to hospital due to coughing fits.
She recovered at home but within two weeks the family were sent a letter that detailed she had low immunity.
Amina said that little Shahera had a rash on her face and said doctors then had to do a biopsy.
They were scratching their heads really. After a biopsy they found that she was an unusual case.
3
Her skin was pretty bad at that point and they gave her steroids and antibiotics.
At the Evelina hospital they ran further tests on Shahera, but sadly she then had to be hospitalised for bacterial sepsis.
Amina said that all of this happened during the 2018 World Cup and said she remembers it so well as temperatures were soaring and she was trying to control little Shaheras temperature.
She was so thirsty and her temperature was 38/39C.
How to join the stem cell register
Little Shahera needs a stem cell donor - here's how you can register
You can join the stem cell register online. All you need to do is fill out a registration form and you will be sent out some swabs.
You will need to take some samples, usually from the inside of your mouth and then send them back. As soon as they are received you'll be added to the register.
You'll remain on the register until you are 61-years-old.
If you are a match for someone in need charities such as Anthony Nolan will help guide you through the process.
Around 90 per cent of people are able to donate via their blood stream with 10 per cent donating from bone marrow while under general anaesthetic.
To find out more and to register you can visit the below sites:
Then the hospital found that one of her white blood cells was completely wiped out, she was very sick and it was at that point that the doctors mentioned a bone marrow transplant.
Once again Shahera was allowed to return home and she made a good recovery.
Then when she was just one her rash appeared again and more tests found that she had a rare immunodeficiency.
Shahera now has antibody immunoglobulin treatments every week and Amina said this makes a big difference to her quality of life.
3
The issue now Amina says, is that doctors need to find a way to continue to treat Shahera so she can do all the things that other little girls can.
Doctors have given the family several months to find a donor and have said the transplant could take place as early as next spring.
Finding a donor though will be a struggle for the family as just 20 per cent of patients from BAME backgrounds find the best possible donor match.
This is in comparison to 69 per cent for people with white European heritage.
Finding a donor would be a big relief for us, because hopefully it will maker her better
Shahera is of Bangladeshi origin and Amina said its difficult for the family to find someone from their community.
We are part of her journey and it has been difficult but we have been very patient and we are still working with consultants and professors.
At the moment she is doing as well as she can be and she has been shielding due to Covid-19.
Finding a donor would be a big relief for us, because hopefully it will maker her better.
Amina said that the family are not only campaigning to find a donor for Shahera but for others in the same situation.
What is immunoglobulin therapy?
Little Shahera has to have antibody immunoglobulin treatments to keep her well
It is a blood-based treatment that contains antibodies in order to fight against infections.
People are given this treatment when their immune systems do not produce enough antibodies.
Some patients are at a higher risk than others.
Charity PID UK states: "Clinical trials have shown that for people with immune deficiency, immunoglobulin treatments result in fewer infections, and those infections that do occur tend to be less serious.
"There is also evidence that people with immune deficiency are more likely to enjoy good health over many years if they receive immunoglobulin correctly. Finally, your wellbeing and your energy levels are likely to be better if you are on immunoglobulin.
"It may take several months before you feel these benefits.
Everything has been put on hold because of Covid but donating is such a simple process.
A lot of people have misconceptions about stem cell donation, but donors can save lives.
Due to the coronavirus lockdown little Shahera has spent lots of quality time with her family.
Amina said she is doing well and has enjoyed spending even more time with her older brother.
She likes to play cops and robbers and fireman Sam but she also enjoys doing girly things too like looking after her dolls.
Now that Shahera is a little bit older, Amina said she is more aware of her rash and will sometimes look at it and point.
She is very aware of the transfusions and understands what is happening and she is very well known in the ward.
She doesnt really cry when they prepare her for transfusions.
A lot of people say she has been through the wars and she has, she hasnt had an easy childhood and theres always something new with her illness.
Exclusive
SILVER LOFT LININGHomeowners to get 5,000 vouchers to insulate homes under green scheme
KIDS ARE ALL RIGHTGovt to subsidise the wages of under-25s to help 350,000 find jobs
SHOWDOWNDepp 'called himself "the monster" when he attacked Amber Heard in violent rages'
STAMPED OUTRishi Sunak to cut stamp duty TOMORROW after fears of stalled housing market
BAT OUT OF HELLPic of human-sized bat is NOT fakebut still may not be as it seems
Latest
HOPE SPREADSCorona deaths fall in all but one area of England & Wales as toll rises by 155
But shes a tough little girl and she is doing really well.
Sarah Rogers, register development manager at Anthony Nolan says: Little Shahera wants to go to nursery, learn and make more friends just like other toddlers olds across the UK. For this to happen she needs a stranger to donate their stem cells.
"If youre aged 16-30 you can join the register online and well send you a cheek swab in the post.
"If youre found to be a match for a patient, you could donate your stem cells and give hope to families like Shaheras. Your support could help us give a patient, their family and their friends a second chance of life."
Continued here:
One common infection could kill our baby girl but one simple act could change her life forever - The Sun
Growing Demand for Myelofibrosis Treatment Market to Significantly Increase Revenues Through 2022 – Jewish Life News
By daniellenierenberg
Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.
To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/11341
The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.
The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:
To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/11341
As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.
On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.
Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.
To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/11341
Some of the key market players in the global myelofibrosis treatment market are
Read more from the original source:
Growing Demand for Myelofibrosis Treatment Market to Significantly Increase Revenues Through 2022 - Jewish Life News
Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells – PR…
By daniellenierenberg
LONDON, July 6,2020 /PRNewswire/ --IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1
The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.
Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."
It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.
Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."
"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem,"concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.
More About the Study1
In addition to this research, IVI are presenting three more studies at the ESHRE Congress:
These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7
More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients
To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.
IVIRMA Global and IVI London, UK
IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.com https://ivi-fertility.co.uk/
References
Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg
SOURCE IVIRMA
See the original post:
Breakthrough study demonstrates the 're-awakening' of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells - PR...
Poseida Therapeutics sets terms for upcoming IPO, aims to raise $150M for cancer treatments – The San Diego Union-Tribune
By daniellenierenberg
Poseida Therapeutics, which is developing targeted treatments for blood-based and other cancers, set the terms for its initial public stock offering expected this week, where it is seeking to raise $150 million.
The San Diego-based company has one drug advancing to Phase 2 clinical trials for multiple myeloma, a type of cancer that develops in certain cells in the bone marrow.
The company expects to file for investigational new drug authorization with the U.S. Food and Drug Administration for its myeloma treatment later this year.
It also is developing other cancer therapies, including treatments for solid tumors and prostate cancer.
Poseida Therapeutics looks to become the third San Diego life science company to go public in the past two months, joining Progenity and Avidity Biosciences. Its stock offering highlights that investor appetite for new biotech companies remains strong in the midst of stock market turbulence from the coronavirus pandemic.
At the end of March, the company employed 149 workers, including 86 with advanced college degrees.
Since its inception, the company has raised $334 million from life sciences institutional investors who support its drug development efforts, including $75 million from Swiss pharmaceutical giant Novartis.
Poseida set the price for its initial public stock offering at $14 to $16 per share. It plans to trade under the ticker symbol PSTX on the Nasdaq exchange. If its shares get out at the midpoint of that range, Poseida Therapeutics would achieve a market value of $890 million.
Founded in 2015, Poseida Therapeutics is making its own version of what are called CAR T cells immune cells genetically engineered to fight cancers. It is developing CAR T cell treatments made from cancer patients own cells.
The process produces stem cell memory T cells. These T cells stick around, both replenishing their population and creating more differentiated group of T cells to attack cancers. They can potentially resume activity if the cancer recurs. This persistence makes it possible to produce the activity needed to eradicate tumors, which up to this point has been beyond the reach of this type of therapy.
The company has its roots in Transposagen Biopharmaceuticals, which founder Eric Ostertag ran for 13 years. Poseida was spun out to pursue gene engineering technologies.
Other members of the companys management teams have worked in executive roles at San Diego biotech firms including Amylin Pharmaceuticals, Halozyme Therapeutics and Mirati Therapeutics.
In addition to Novartis, additional investors include Adage Capital, Aisling Capital, Boxer Capital, Fidelity, Longitude Capital, Malin Corp., Millennium Capital, Pentwater Capital, Perceptive Advisors, Schonfeld and Vivo Capital.
Bank of America Securities, Piper Sandler and William Blair are joint underwriters on the initial public stock offering.
See original here:
Poseida Therapeutics sets terms for upcoming IPO, aims to raise $150M for cancer treatments - The San Diego Union-Tribune
CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United…
By daniellenierenberg
This Agreement will allow for immediate distribution of leronlimab to patients for the treatment of COVID-19 upon successful completion of CytoDyn’s ongoing clinical trials and FDA approval
VANCOUVER, Washington, July 06, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn” or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has signed an exclusive Distribution and Supply Agreement with American Regent, Inc. (American Regent”) for the distribution of leronlimab for the treatment of COVID-19 in the United States.
Under the terms of the agreement, CytoDyn will supply leronlimab for the treatment of COVID-19 for distribution by American Regent and receive quarterly payments based on a profit-sharing arrangement.
Having this distribution agreement in place ahead of the readout from CytoDyn’s COVID-19 clinical trials further emphasizes CytoDyn’s commitment to making leronlimab immediately available to patients based on the successful completion of its ongoing clinical trials,” said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. We are particularly happy to be partnering with a company with the proven expertise, unparalleled commercial reach and stellar reputation of American Regent.”
American Regent is looking forward to partnering with CytoDyn to provide COVID-19 patients rapid and efficient access to a potentially life-saving drug,” said Mr. Harsher Singh, American Regent’s Vice President and Chief Commercial Officer.
CytoDyn is currently enrolling a Phase 2b/3 clinical trial for 390 severe and critically ill COVID-19 patients, which is a randomized, placebo-controlled with 2:1 ratio (active drug to placebo ratio). The Company has also completed its enrollment of a Phase 2 randomized clinical trial with 75 patients in the mild-to-moderate COVID-19 population. CytoDyn has been granted more than sixty emergency Investigational New Drug (eIND) authorizations by the U.S. Food and Drug Administration (FDA) and plans to provide clinical updates for this patient population in the coming weeks.
About American Regent American Regent, Inc., a Daiichi Sankyo Group company, is a top-10 injectable manufacturer. For over 50 years, American Regent has been developing, manufacturing and supplying quality generic and branded injectables for healthcare providers. For nearly 20 years, American Regent have been a leader in IV iron therapy. American Regent is committed to U.S.-based manufacturing. In 2018, more than 99% of units supplied were manufactured in its U.S.-based facilities making it uniquely positioned to quickly mobilize and respond to shortages or changes in market needs. Speed counts. Flexibility matters. Reliability and quality are paramount. Because patients should never have to wait for the medications they need. For more information, please visit http://www.americanregent.com.
About Coronavirus Disease 2019 CytoDyn has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and enrollment continues in its Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.
SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.
About Leronlimab (PRO 140) and BLA Submission for the HIV Combination Therapy The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).
In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.
The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May 11, 2020. After the FDA deems a BLA submission complete, it sets a PDUFA goal date. CytoDyn has Fast Track designation for leronlimab and a rolling review for its BLA, as previously assigned by the FDA. The Company filed a request for Priority Review designation for its BLA to shorten the FDA’s review time from 10 to 6 months, an FDA goal for BLA applications given Priority Review designation.
In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.
The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug” designation to leronlimab for the prevention of GvHD.
About CytoDyn CytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn filed its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients, and submitted additional FDA requested clinical datasets on May 11, 2020. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV. No drug-related serious site injection reactions reported in about 800 patients treated with leronlimab and no drug-related SAEs reported in patients treated with 700 mg dose of leronlimab. Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.
Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes,” hopes,” intends,” estimates,” expects,” projects,” plans,” anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Company’s cash position, (ii) the Company’s ability to raise additional capital to fund its operations, (iii) the Company’s ability to meet its debt obligations, if any, (iv) the Company’s ability to enter into partnership or licensing arrangements with third parties, (v) the Company’s ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Company’s ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Company’s clinical trials, (viii) the results of the Company’s clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Company’s products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Company’s control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.
CYTODYN CONTACTS Investors: Cristina De Leon Office: 360.980.8524, ext. 106 Mobile: 503.214.0872 cdeleon@cytodyn.com
See original here:
CytoDyn Announces Execution of Exclusive Agreement with American Regent for Distribution and Supply of Leronlimab for Treatment of COVID-19 in United...
Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision – Stockhead
By daniellenierenberg
The worlds biggest listed pure-play stem cell developer has a busy slate of clinical work, notably in therapies for advanced heart failure, chronic back pain and graft-versus-host disease (GvHD).
Now these programs are approaching a thrilling denouement and, as the Demtel man enthused, theres more: Mesoblast (ASX:MSB) is also undertaking an expanded coronavirus trial after a 12-patient effort showed promising results in treating acute respiratory distress syndrome (Ards), the usual cause of death with COVID-19.
The patients received infusions of Mesoblasts allogeneic (off the shelf) mesenchymal stem cell candidate, remestemcel-L, acquired from Osiris for $106m in 2013.
Meanwhile, results from two phase III trials are expected this (September) quarter: a 566-patient effort for chronic heart failure and a 404-patient trial for chronic lower back pain caused by disc degeneration.
And in September, the US Food and Drug Administration will rule on whether or not the company can market its GvHD therapy on American shores.
Mesoblast founder and CEO Prof Silviu Itescu notes that across all its therapies the company is targeting the most severe cases where alternative therapies dont exist.
Mesoblasts proprietary process selects precursor and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell kitty is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast is targeting a common market across all its disease indications: inflammation. In the case of heart disease, tissue macrophages (cells) churn out inflammatory factors that damage heart muscle and cause fibrosis and vascular dysfunction.
The stem cells respond to severe inflammation by switching the culprit macrophages off and converting them to nice cells that actually protect the heart muscle.
This is the central mechanism in each of our disease states: heart failure, back pain, GvHD and rheumatoid arthritis, Professor Itescu says. We have the potential to make a big difference in some very big disease states where inflammation is central.
Backed by the Pratt familys listed investment vehicle Thorney Investments, Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5bn in 2011 before suffering a reality check.
Culprits included a phase II heart trial that failed to meet primary endpoints, a badly executed Nasdaq listing and Israel pharma house Teva Pharmaceuticals decision to walk away from a heart program partnership in 2016.
Mesoblast dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The companys Ards and GvHD programs are based on mesenchymal stem cell assets acquired from US pharma group Osiris Therapeutics in October 2013.
Mesoblasts own-developed cells are called mesenchymal precursor cells and they are being developed for rheumatoid arthritis and diabetic nephropathy, as well as the aforementioned heart failure and lower back pain programs.
Ards is bought on by an excessive immune response to the virus in the lungs. The immune cells produce inflammatory cytokines, which destroy lung tissue and can also damage the liver, kidney and heart.
Remestemcell-L has the potential to tame the cytokine storm in Ards and may offer a life-saving treatment for those unfortunate individual sufferers of COVID-19 Ards, Professor Itescu says.
Mesoblasts COVID-19 proclamations have been coming so thick and fast that its been Ard(s) just to keep up. But the core excitement cluster was around Mesoblasts April 23 disclosure of the results of the trial at New Yorks Mt Sinai Hospital, covering moderate to acute Ards cases.
Under the compassionate use protocol, the patients were treated with two infusions of remestemcel-L over the first five days.
The results? Nine of the 12 patients came off a ventilator within a median 10 days, with 83 per cent survival (the Grim Reapers spin on this is that two of them died).
In comparison, only 9 per cent of patients at one reference hospital (38 out of 445 patients) were able to come off the ventilator with standard-of-care treatment.
Another US hospital reported that only 38 patients of 320 or 12 per cent survived.
Of course, 12 people good and true are adequate numbers for a jury, but sub-optimal to comprise a statistically significant trial.
Thus, the company is enrolling 300 patients in a phase III, randomised, controlled trial of severe Ards patients at 30 sites.
The first patients were dosed in early May, with about 15 sites established as the company chases the disease from the northeast to the southern states.
Mesoblast chief medical officer Professor Fred Grossman says the company is carefully choosing hot spots such as Alabama which, as of late May had the no vacancy signs outside its intensive care wards.
The sites are recruiting quite quickly, he says. There is a tremendous interest in this study.
The trial leaders will undertake an interim analysis at 30 days, and when 30 per cent of patients have reached their primary endpoint. At that point the trial can be dumped on futility grounds, or expanded to the control group because it appears to be working.
Remestemcell-L has investigational new drug (IND) status with the US Food and Drug Administration, meaning the company swiftly can initiate trials on patients with very dismal prospects.
Long-suffering Mesoblast investors will recall that the companys shares tumbled 28 per cent in November 2018 after a 159-patient trial of Rexlemestrocel-L (Revascor) for end-stage heart failure did not meet its primary endpoint of weaning patients from left ventricle assist devices (LVADs or heart pumps).
The company claimed the endpoint was set by the independent !!! investigators and was of little real clinical interest. What really mattered was that the trial showed reduced gastrointestinal bleeding by 76 per cent and hospitalisations by 65 per cent.
Investors are now nervously awaiting the first readout of the broader 566-patient chronic heart failure trial across 59 US sites.
Mesoblast targeted patients with class three or four disease, the sickest 15 to 20 per cent of patients who have failed standard-of-care drugs.
Class three patients have a 20 per cent chance of dying within two years while with class four its a case of flip a coin that you will be around in 12 months.
At this stage, Mesoblast retains its heart treatment rights except in China, where it is partnered with Tasly Pharmaceutical.
Mesoblasts phase III back pain trial aimed to enroll 404 patients with lower back pain caused by degenerative disc disease.
The endpoint of the trial, dubbed MPC-06-ID, is an improvement in pain and function over 24 months.
As with the heart trial, results are imminent and its a toss-up as to what release will hit the ASX announcements feed first.
The company is liaising with its global back pain partner Grunenthal GmbH about the clinical protocol for a European phase III confirmatory trial.
In Japan, Mesoblast is partnered with JCR Pharmaceutical for its approved GvHD treatment called Temcell and its off and racing in that smallish but enthusiastic market.
Meanwhile, the company is angling to enter the US market for a similar GvHD treatment, branded Ryoncil.
GvHD afflicts about half of the 30,000 patients annually undergoing allogeneic bone marrow transplant, typically for blood cancers, with their bodies rejecting the alien transplant.
In March, the FDA granted priority review with a September 30 action date, but we might have a good idea of the outcome in August.
Why? Because thats when the FDAs relevant advisory committee meets to vote on the matter and the (virtual) gathering is open to the public.
A date is yet to be set. While advisory committee views are not binding on the FDA, they usually presage the final decision.
If approved, Mesoblast could be selling Ryoncil in the US by the time were carving the Christmas turkey (badly, in the case of your columnist).
Buoyed by the COVID-19 results, Mesoblast in May wasted no time tapping institutional investors for an idle $US90m ($129.6m) in a placement.
Mesoblast already had a healthy cash balance of $US60m.
The raising was struck at $3.20 a share, a modest 7 per cent discount to the prevailing price.
The funds, in the main, will be used to scale-up manufacturing of remestemcell-L and to support the phase III trial, as well as for working capital and general corporate purposes.
The company also has $US67m available through existing financing facilities and partnerships.
Mesoblast reported revenue of $US31.45m for the nine months to March 2020, up 113 per cent. The reported loss narrowed 34 per cent to $US45.3m, reflecting curtailed research and development spend by $US7.5m, or 15 per cent.
The revenue included $US5.9m of JCR royalties from Temcell sales in Japan and milestone revenue of $US25m.
The company stands to pocket up to $US150m of royalties and milestones from Grunenthal prior to any European launch of Revascor.
Successful sales could result in up to $US1bn in milestone payments.
Over the last decade, Mesoblasts ASX shares have traded as high as $9 (October 2011) and as low as $1.03 (December last year).
To the Meso-sceptics the company has promised far too much with limited commercial success, while raising $1bn since listing 16 years ago.
Dare we say that Mesoblast now looks more focused and to be getting somewhere?
When we last covered Mesoblast in March 2019, Professor Itescu said he was 95 per cent certain the company would do what no other Aussie biotech in phase III had done: win FDA drug approval.
Well, Clinuvel has stolen that Aussie first honour, but Mesoblast is well placed to get over the line with a GvHD treatment in the US, which presents a market eight times the size of Japans.
Its certainly rare for a biotech to expect results for three major trials and a key regulatory decision in the space of months.
If the heart and back pain results are definitively positive and the FDA green lights GvHD, the company hits the jackpot. If two or more of them bomb lets not go there.
Your ultra conservative columnist regards the COVID-19 stuff as the icing on the cake with an outside chance of success, especially given the hundreds of other programs in the coronavirus-busting sector.
Disclosure: Dr Boreham is not a qualified medical practitioner and does not possess a doctorate of any sort. But he hopes to become proficient in turkey carving by December 25.
This column first appeared in Biotech Daily.
Get the latest Stock & Small Caps news and insights direct to your inbox.
It's free. Unsubscribe whenever your want.
You might be interested in
Continue reading here:
Dr Borehams Crucible: Mesoblast within months of 3 major trial results, key regulatory decision - Stockhead
Bone Marrow Processing Systems Market Expansion Projected to Gain an Uptick during COVID-19 Crisis 2018 2025 – Kentucky Journal 24
By daniellenierenberg
Bone marrow aspiration and trephine biopsy are usually performed on the back of the hipbone, or posterior iliac crest. An aspirate can also be obtained from the sternum (breastbone). For the sternal aspirate, the patient lies on their back, with a pillow under the shoulder to raise the chest. A trephine biopsy should never be performed on the sternum, due to the risk of injury to blood vessels, lungs or the heart.
Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/3374
The need to selectively isolate and concentrate selective cells, such as mononuclear cells, allogeneic cancer cells, T cells and others, is driving the market. Over 30,000 bone marrow transplants occur every year. The explosive growth of stem cells therapies represents the largest growth opportunity for bone marrow processing systems.
Europe and North America spearheaded the market as of 2018, by contributing over 74.0% to the overall revenue. Majority of stem cell transplants are conducted in Europe, and it is one of the major factors contributing to the lucrative share in the cell harvesting system market.
In 2018, North America dominated the research landscape as more than 54.0% of stem cell clinical trials were conducted in this region. The region also accounts for the second largest number of stem cell transplantation, which is further driving the demand for harvesting in the region.
Asia Pacific is anticipated to witness lucrative growth over the forecast period, owing to rising incidence of chronic diseases and increasing demand for stem cell transplantation along with stem cell-based therapy. Japan and China are the biggest markets for harvesting systems in Asia Pacific. Emerging countries such as Mexico, South Korea, and South Africa are also expected to report lucrative growth over the forecast period. Growing investment by government bodies on stem cell-based research and increase in aging population can be attributed to the increasing demand for these therapies in these countries.
Major players operating in the global bone marrow processing systems market are ThermoGenesis (Cesca Therapeutics inc.), RegenMed Systems Inc., MK Alliance Inc., Fresenius Kabi AG, Harvest Technologies (Terumo BCT), Arthrex, Inc. and others..
COVID-19 Impact Analysis@https://www.trendsmarketresearch.com/report/covid-19-analysis/3374
See more here:
Bone Marrow Processing Systems Market Expansion Projected to Gain an Uptick during COVID-19 Crisis 2018 2025 - Kentucky Journal 24
Covid 19 Impact On Global Bone Marrow Aspirate Concentrates (BMAC) Market: Industry Analysis and forecast (2019 to 2026): By product Type,…
By daniellenierenberg
Global Bone Marrow Aspirate Concentrates Marketwas valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 6.5 % during forecast period of 2019 to 2026
REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample//37078/
Bone marrow concentrate (BMC) uses stem cells that are harvested from your own bone marrow to help the body heal itself. These cells when injected directly into an injury site, prompt a rapid and efficient restoration of the tissue, returning it to a more healthy state by stimulating the bodys natural healing response. It is non-surgical treatment for various orthopedic injuries, including mild to moderate osteoarthritis, disc degeneration and soft tissue injuries.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.
Global Bone Marrow Aspirate Concentrates Market Drivers and RestrainsBone marrow-derived stem cell treatment is considered a promising and advanced therapy. It reduces the injury healing time in orthopedic diseases to five to six weeks from four to six months in case of surgery. Reduction in the healing time is a factor likely to fuel the Bone Marrow Aspirate Concentrates market during the forecast period.
Pain associated with the treatment, lack of awareness, and use of alternative treatments are major restraints to the Global Bone Marrow Aspirate Concentrates Market. Furthermore, increased investments in R&D and clinical trials attributed to slow approval processes entailing sunken costs, and marginal returns on investment for manufacturers are factors hindering Global Bone Marrow Aspirate Concentrates Market.
Global Bone Marrow Aspirate Concentrates Market key segmentationBy end-use market is divided into hospitals & clinics, pharmaceutical & biotechnology companies, Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs), and academic & research institutes. The hospitals & clinics segment dominated the bone marrow aspirate concentrates market in 2018 and is expected to maintain its dominance during the forecast period. The hospitals & clinics segmental growth is boosted by the biotechnology & biopharmaceutical companies in terms of revenue during the forecast period. Growth of the segment is attributed to increasing number of biotechnology companies and rising partnerships among the market players to expand globally.
DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying//37078/
Global Bone Marrow Aspirate Concentrates Market regional analysisBy regional analysis, global bone marrow aspirate concentrates market is divided into major five geographical regions, including North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. North America held largest share of the Global Bone Marrow Aspirate Concentrates market owing to technological advancements and regulatory approval for new devices, rising awareness about stem cell therapy, and number of cosmetic surgical procedures. Furthermore, Asia Pacific orthopedic market is key driver, which led to this massive and augmented growth. The orthopedic market in Asia including bone graft, spine, and bone substitute is anticipated to grow as fast as the overall orthopedic market which will further boost growth of BMAC market in the region during forecast period.
The objective of the report is to present comprehensive analysis of Global Bone Marrow Aspirate Concentrates Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.
The report also helps in understanding Global Bone Marrow Aspirate Concentrates Market dynamics, structure by analyzing the market segments, and project the Global Bone Marrow Aspirate Concentrates Market size. Clear representation of competitive analysis of key players by Bone Marrow Aspirate Concentrates Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Bone Marrow Aspirate Concentrates Market make the report investors guide.Global Bone Marrow Aspirate Concentrates Market by product type
Bone Marrow Aspirate Concentrates Systems Bone Marrow Aspirate Concentrates AccessoriesGlobal Bone Marrow Aspirate Concentrates Market Application
Orthopaedic Surgery, Wound Healing, Chronic Pain, Peripheral Vascular Disease, Dermatology;Global Bone Marrow Aspirate Concentrates Market by region
Asia Pacific North America Europe Latin America Middle East AfricaGlobal Bone Marrow Aspirate Concentrates Market by end-user
Hospitals & Clinics Pharmaceutical & Biotechnology Companies Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) Academic & Research InstitutesKey players operating on Global Bone Marrow Aspirate Concentrates Market
Terumo Corporation (Terumo BCT), Ranfac Corp., Arthrex, Inc., Globus Medical, Inc., Cesca Therapeutics Inc., MK Alliance Inc. (TotipotentSC), and Zimmer Biomet Holdings, Inc Cesca Therapeutics Inc. Stryker Paul Medical Systems LIFELINX SURGIMED PVT. LTD.
MAJOR TOC OF THE REPORT
Chapter One: Bone Marrow Aspirate Concentrates Market Overview
Chapter Two: Manufacturers Profiles
Chapter Three: Global Bone Marrow Aspirate Concentrates Market Competition, by Players
Chapter Four: Global Bone Marrow Aspirate Concentrates Market Size by Regions
Chapter Five: North America Bone Marrow Aspirate Concentrates Revenue by Countries
Chapter Six: Europe Bone Marrow Aspirate Concentrates Revenue by Countries
Chapter Seven: Asia-Pacific Bone Marrow Aspirate Concentrates Revenue by Countries
Chapter Eight: South America Bone Marrow Aspirate Concentrates Revenue by Countries
Chapter Nine: Middle East and Africa Revenue Bone Marrow Aspirate Concentrates by Countries
Chapter Ten: Global Bone Marrow Aspirate Concentrates Market Segment by Type
Chapter Eleven: Global Bone Marrow Aspirate Concentrates Market Segment by Application
Chapter Twelve: Global Bone Marrow Aspirate Concentrates Market Size Forecast (2019-2026)
Browse Full Report with Facts and Figures of Bone Marrow Aspirate Concentrates Market Report at:https://www.maximizemarketresearch.com/market-report/global-bone-marrow-aspirate-concentrates-bmac-market/37078/
About Us:
Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.
Contact info:
Name: Vikas Godage
Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.
Email: sales@maximizemarketresearch.com
Contact: +919607065656/ +919607195908
Website: http://www.maximizemarketresearch.com
Read more here:
Covid 19 Impact On Global Bone Marrow Aspirate Concentrates (BMAC) Market: Industry Analysis and forecast (2019 to 2026): By product Type,...
28 cool health things that started with a Canadian – Regina Leader-Post
By daniellenierenberg
A special thank you to Kathleen Dickson and Dr. John Bergeron for pointing out that yes, indeed, there are also many women who have made and continue to make significant contributions to health. We have added their additions below, but this list is by no means complete.
From open heart surgery to child-resistant containers, prestigious awards and bombs (not that kind), Canada has a long history of Canadians whose ideas and inventions have played huge roles in defining this nations healthcare.
DNA and cancer
Nada Jabado at McGill affiliated Childrens Hospital is a pioneer in pediatric cancer and her discovery of the role of what is known as the epigenome that marks the DNA in our genes in cancer. She is a leader in innovation in Health research and recognized for her leadership in the application of discoveries to address brain tumours in children.
Insulin
Perhaps the most famous health innovation to come out of Canada, if such a thing can be measured. The arrival of insulin has saved countless lives since its creation in 1922 when Frederick Banting and Charles Best isolated and extracted insulin from the pancreas of dogs. Their Nobel Prize arrived swiftly thereafter in 1923.
Read the original:
28 cool health things that started with a Canadian - Regina Leader-Post
Impacts of the COVID-19-Mesenchymal Stem Cells Market Size Current and Future Industry Trends, 2020-2028 – 3rd Watch News
By daniellenierenberg
A recent report published by QMI on mesenchymal stem cells market is a detailed assessment of the most important market dynamics. After carrying out a thorough research of mesenchymal stem cells market historical as well as current growth parameters, business expectations for growth are obtained with utmost precision. The study identifies specific and important factors affecting the market for mesenchymal stem cells during the forecast period. It can enable manufacturers of mesenchymal stem cells to change their production and marketing strategies in order to envisage maximum growth.
Get Sample Copy of This Report @https://www.quincemarketinsights.com/request-sample-61514?utm_source=3WN&utm_medium=santosh
According to the report, the mesenchymal stem cells market has been segmented by source (bone marrow, umbilical cord blood, peripheral blood, lung tissue, synovial tissues, amniotic fluids, adipose tissues), by application (injuries, drug discovery, cardiovascular infraction, others).Insights about the regional distribution of market:The market has been segmented in major regions to understand the global development and demand patterns of this market.
For the mesenchymal stem cells market, the segments by region are North America, Asia Pacific, Western Europe, Eastern Europe, Middle East, and Rest of the World. During the forecast period, North America, Asia Pacific and Western Europe are expected to be major regions on the mesenchymal stem cells market.
North America and Western Europe have been one of the key regions as they have an established healthcare infrastructure for product innovations and early adaptations. This is estimated to drive demand for the mesenchymal stem cells market in these regions. In addition to this, some of the major companies operating in this market are headquartered in these regions.
Asia Pacific is estimated to register a high CAGR mesenchymal stem cells market. The APAC region has witnessed strategic investments by global companies to cater to the growing demand for healthcare solutions in recent years. The Middle East and Rest of the World are estimated to be emerging regions for the mesenchymal stem cells market.
Make An Inquiry For Purchasing This Report @https://www.quincemarketinsights.com/enquiry-before-buying/enquiry-before-buying-61514?utm_source=3WN&utm_medium=santosh
Market Players Cell Applications, Inc., Cyagen Biosciences Inc. Axol Bioscience Ltd., Cytori Therapeutics Inc., Stem Cell Technologies Inc., Celprogen, Inc.
Reasons to Buy This Report:o It provides niche insights for a decision about every possible segment helping in the strategic decision-making process.o Market size estimation of the mesenchymal stem cells market on a regional and global basis.
o A unique research design for market size estimation and forecast.o Identification of major companies operating in the market with related developmentso Exhaustive scope to cover all the possible segments helping every stakeholder in the mesenchymal stem cells market.
Market Segmentation:By Source:o Bone Marrowo Umbilical Cord Bloodo Peripheral Bloodo Lung Tissueo Synovial Tissueso Amniotic Fluidso Adipose Tissues
By Application:o Injurieso Drug Discoveryo Cardiovascular Infractiono Others
By Region:o North Americao North America, by Country? US? Canada? Mexicoo North America, by Sourceo North America, by Application
o Western Europeo Western Europe, by Country? Germany? UK? France? Italy? Spain? The Netherlands? Rest of Western Europeo Western Europe, by Sourceo Western Europe, by Application
o Asia Pacifico Asia Pacific, by Country? China? India? Japan? South Korea? Australia? Indonesia? Rest of Asia Pacifico Asia Pacific, by Sourceo Asia Pacific, by Application
o Eastern Europeo Eastern Europe, by Country? Russia? Turkey? Rest of Eastern Europeo Eastern Europe, by Sourceo Eastern Europe, by Application
o Middle Easto Middle East, by Country? UAE? Saudi Arabia? Qatar? Iran? Rest of Middle Easto Middle East, by Sourceo Middle East, by Applicationo Rest of the Worldo Rest of the World, by Country? South America? Africao Rest of the World, by Sourceo Rest of the World, by Application
Years Covered in the Study:Historic Year: 2016-2017Base Year: 2018Estimated Year: 2019Forecast Year: 2028
Objectives of this report:o To estimate the market size for mesenchymal stem cells market on a regional and global basis.o To identify major segments in mesenchymal stem cells market and evaluate their market shares and demand.
o To provide a competitive scenario for the mesenchymal stem cells market with major developments observed by key companies in the historic years.o To evaluate key factors governing the dynamics of mesenchymal stem cells market with their potential gravity during the forecast period.Customization:This study is customized to meet your specific requirements:
o By Segmento By Sub-segmento By Region/Countryo Product Specific Competitive Analysis
Contact:Quince Market InsightsAjay D. (Knowledge Partner)Office No- A109Pune, Maharashtra 411028Phone: +91 706 672 4848 +1 208 405 2835 / +44 121 364 6144 /Email: [emailprotected]Web:www.quincemarketinsights.com
ABOUT US:QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.
Follow this link:
Impacts of the COVID-19-Mesenchymal Stem Cells Market Size Current and Future Industry Trends, 2020-2028 - 3rd Watch News
COVID 19 to Lead the Sales of Myelofibrosis Treatment to Register Stellar Growth in the Next 10 Years – The Canton Independent Sentinel
By daniellenierenberg
Myelofibrosis or osteomyelofibrosis is a myeloproliferative disorder which is characterized by proliferation of abnormal clone of hematopoietic stem cells. Myelofibrosis is a rare type of chronic leukemia which affects the blood forming function of the bone marrow tissue. National Institute of Health (NIH) has listed it as a rare disease as the prevalence of myelofibrosis in UK is as low as 0.5 cases per 100,000 population. The cause of myelofibrosis is the genetic mutation in bone marrow stem cells. The disorder is found to occur mainly in the people of age 50 or more and shows no symptoms at an early stage. The common symptoms associated with myelofibrosis include weakness, fatigue, anemia, splenomegaly (spleen enlargement) and gout. However, the disease progresses very slowly and 10% of the patients eventually develop acute myeloid leukemia. Treatment options for myelofibrosis are mainly to prevent the complications associated with low blood count and splenomegaly.
Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/11341
The global market for myelofibrosis treatment is expected to grow moderately due to low incidence of a disease. However, increasing incidence of genetic disorders, lifestyle up-gradation and rise in smoking population are the factors which can boost the growth of global myelofibrosis treatment market. The high cost of therapy will the growth of global myelofibrosis treatment market.
The global market for myelofibrosis treatment is segmented on basis of treatment type, end user and geography:
As myelofibrosis is considered as non-curable disease treatment options mainly depend on visible symptoms of a disease. Primary stages of the myelofibrosis are treated with supportive therapies such as chemotherapy and radiation therapy. However, there are serious unmet needs in myelofibrosis treatment market due to lack of disease modifying agents. Approval of JAK1/JAK2 inhibitor Ruxolitinib in 2011 is considered as a breakthrough in myelofibrosis treatment. Stem cell transplantation for the treatment of myelofibrosis also holds tremendous potential for market growth but high cost of therapy is foreseen to limits the growth of the segment.
On the basis of treatment type, the global myelofibrosis treatment market has been segmented into blood transfusion, chemotherapy, androgen therapy and stem cell or bone marrow transplantation. Chemotherapy segment is expected to contribute major share due to easy availability of chemotherapeutic agents. Ruxolitinib is the only chemotherapeutic agent approved by the USFDA specifically for the treatment of myelofibrosis, which will drive the global myelofibrosis treatment market over the forecast period.
You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/11341
Geographically, global myelofibrosis treatment market is segmented into five regions viz. North America, Latin America, Europe, Asia Pacific and Middle East & Africa. Northe America is anticipated to lead the global myelofibrosis treatment market due to comparatively high prevalence of the disease in the region.
Some of the key market players in the global myelofibrosis treatment market are Incyte Corporation, Novartis AG, Celgene Corporation, Mylan Pharmaceuticals Ulc., Bristol-Myers Squibb Company, Eli Lilly and Company, Taro Pharmaceuticals Inc., AllCells LLC, Lonza Group Ltd., ATCC Inc. and others.
Rustil is a regular contributor to blog , Specializing in Industry Research and Forecast
Stem Cell Therapy Market 2020 to Witness Lucrative Growth in Coming Years with Top Key Players RichSource, Mesoblast Limited, TiGenix NV, AlloSource -…
By daniellenierenberg
Stem Cell Therapy Market In-Depth Analysis
Stem cells are preliminary body cells from which all other cells with specialized functions are generated. Under controlled environment in the body or a clinical laboratory, these cells divide to form more cells called daughter cells. Due to the advent of modern health science, these cells play a major role in understanding the occurrence of diseases, generation of advanced regenerative medicines, and drug discovery. There are certain sources such as embryo, bone marrow, body fats, and umbilical cord blood amongst others, where stem cells are generated. The globalstem cell therapy marketis driven by factors such as increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines. However, high cost related with stem cell therapy is likely to obstruct the growth of the stem cell therapy market during the forecast period. The growing research and development activities in Asia Pacific region is expected to offer huge growth opportunity for stem cell therapy market.
Request Sample Copy of Stem Cell Therapy Market at: https://www.theinsightpartners.com/sample/TIPHE100000991/
Some of the key players profiled in the study are MEDIPOST, Pharmicell Co., Inc., RichSource, BioTime Inc. (Lineage Cell Therapeutics, Inc.), Mesoblast Limited, Holostem Terapie Avanzate Srl, U.S. Stem Cell, Inc., Caladrius Biosciences, Inc., TiGenix NV, AlloSource, etc.
The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Stem Cell Therapy market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.
Global Stem Cell Therapy Market to 2027 Global Analysis and Forecast by Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Other Stem Cell Therapy); Treatment (Allogeneic, Autologous ); Application (Musculoskeletal, Dermatology, Cardiology, Drug Discovery and Development, Other Applications); End User (Hospitals and Specialty Clinics, Academic and Research Institutes)
Key Benefits
The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Stem Cell Therapy market. The researcher provides an extensive analysis of the Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.
Competitive scenario:
The study assesses factors such as segmentation, description, and applications of Stem Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.
Scope of the Report
The research on the Stem Cell Therapy market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Stem Cell Therapy market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.
Promising Regions & Countries Mentioned in The Stem Cell Therapy Market Report:
Major highlights of the report:
All-inclusive evaluation of the parent market
Evolution of significant market aspects
Industry-wide investigation of market segments
Assessment of market value and volume in past, present, and forecast years
Evaluation of market share
Study of niche industrial sectors
Tactical approaches of market leaders
Lucrative strategies to help companies strengthen their position in the market
Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPHE100000991/
Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.
We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget
Contact Us:
The Insight Partners,
Phone: +1-646-491-9876
Email: [emailprotected]
See the original post:
Stem Cell Therapy Market 2020 to Witness Lucrative Growth in Coming Years with Top Key Players RichSource, Mesoblast Limited, TiGenix NV, AlloSource -...
Zinc finger and BTB domain-containing protein 46 is essential for survival and proliferation of acute myeloid leukemia cell line but dispensable for…
By daniellenierenberg
Zinc finger and BTB domain-containing protein 46 (Zbtb46) is a transcription factor identified in classical dendritic cells, and maintains dendritic cell quiescence in a steady state. Zbtb46 has been reported to be a negative indicator of acute myeloid leukemia (AML). We found that Zbtb46 was expressed at a relatively higher level in hematopoietic stem and progenitor cells (HSPCs) compared to mature cells, and higher in AML cells compared to normal bone marrow (BM) cells. However, the role of Zbtb46 in HSPCs and AML cells remains unclear. Therefore, we sought to elucidate the effect of Zbtb46 in normal hematopoiesis and AML cells.We generated Zbtb46 and Zbtb46Mx1-Cre mice. The deletion of Zbtb46 in Zbtb46Mx1-Cre mice was induced by intraperitoneal injection of double-stranded poly (I). poly (C) (poly(I:C)), and referred as Zbtb46 cKO. After confirming the deletion of Zbtb46, the frequency and numbers of HSPCs and mature blood cells were analyzed by flow cytometry. Serial intraperitoneal injection of 5-fluorouracil was administrated to determine the repopulation ability of HSCs from Zbtb46 and Zbtb46 cKO mice. The correlation between Zbtb46 expression and prognosis was analyzed using the data from the Cancer Genome Atlas. To investigate the role of Zbtb46 in AML cells, we knocked down the expression of Zbtb46 in THP-1 cells using lentiviral vectors expressing small hairpin RNAs targeting Zbtb46. Cell proliferation rate was determined by cell count assay. Cell apoptosis and bromodeoxyuridine incorporation were determined by flow cytometry.The percentages and absolute numbers of HSPCs and mature blood cells were comparable in Zbtb46 cKO mice and its Zbtb46 littermates (Zbtb46vs. Zbtb46 cKO, HPC: 801,31084,282 vs. 907,20297,403, t = 0.82, P = 0.46; LSK: 86,8957802 vs. 102,2105025, t=1.65, P=0.17; HSC: 19,7533116 vs. 17,6083508, t=0.46, P=0.67). The repopulation ability of HSCs from Zbtb46Mx1-Cre mice was similar to those from Zbtb46 control (P=0.26). Zbtb46 had elevated expression in AML cells compared to total BM cells from normal control. Knockdown of Zbtb46 in THP-1 cells led to a significant increase in cell apoptosis and reduced cell growth and proliferation.Collectively, our data indicate that Zbtb46 is essential for survival and proliferation of AML cells, but dispensable for normal hematopoiesis.
PubMed
Read the original post:
Zinc finger and BTB domain-containing protein 46 is essential for survival and proliferation of acute myeloid leukemia cell line but dispensable for...